<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:regn="http://regeneron.com/20220302">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_regn_regeneron.com_20220302 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20220302_20220302 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="regn-20220302.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-02to2022-03-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-02</xbrli:startDate>
        <xbrli:endDate>2022-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220302__20220302_z7gqZXaxnVJk"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): March 8, 2022 (<span id="xdx_907_edei--DocumentPeriodEndDate_c20220302__20220302_zfI18PGLPkBe"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 2, 2022</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20220302__20220302_zVGYrFcnYPxj"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20220302__20220302_zvjX6HB2WIc4"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></span></td>
    <td style="width: 59%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20220302__20220302_zYMvbfhifk17"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220302__20220302_zQFpD1cnVX41"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220302__20220302_zIqYkege07c1"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20220302__20220302_zEvAtzlhe4pa"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20220302__20220302_zLZD3x5urOg9"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20220302__20220302_zljRukDBPdx3"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices, including zip code)</span></td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90B_edei--CityAreaCode_c20220302__20220302_zGptJpCAsvel"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20220302__20220302_zyfPAK6PS0I1"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--WrittenCommunications_c20220302__20220302_zNRUTPValMn6"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20220302__20220302_zTzWmwqGDQ3g"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20220302__20220302_zfuybNjzmTS"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20220302__20220302_zEFArOTmuO2k"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; vertical-align: bottom; font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Name
    of each exchange<br />
    on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20220302__20220302_zVSkxs2B4swe"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20220302__20220302_zhfoVxtLrdr"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20220302__20220302_z5VvDHyWiB4f"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220302__20220302_zj9YskrecE8l"><ix:nonNumeric contextRef="From2022-03-02to2022-03-02" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March&#160;2, 2022, Regeneron Pharmaceuticals,&#160;Inc.
(&#8220;Regeneron&#8221; or the &#8220;Company&#8221;) and/or certain of its subsidiaries entered into certain agreements related to a
five-year extension of the term of a $720.0 million lease financing that was originally completed on March&#160;3, 2017 for the Company&#8217;s
existing corporate headquarters and other rentable area consisting of approximately 150 acres of predominately office buildings and laboratory
space located in the towns of Mount Pleasant and Greenburgh, New York (the &#8220;Facility&#8221;). In 2016, the Company entered into
a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the then lessor, pursuant to which the Company agreed to purchase the
Facility for a purchase price of $720.0 million. In March&#160;2017, Old Saw Mill Holdings LLC, a wholly owned subsidiary of the Company
(the &#8220;Lessee&#8221;), entered into a Participation Agreement (as previously amended and restated, the &#8220;Original Participation
Agreement&#8221;) with Bank of America, N.A., as administrative agent (in such capacity, the &#8220;Administrative Agent&#8221;), BA Leasing
BSC, LLC, an affiliate of Banc of America Leasing&#160;&amp; Capital, LLC, as lessor (in such capacity, the &#8220;Lessor&#8221;), and
a syndicate of lenders, which provided for lease financing in connection with the acquisition by the Lessor of the Facility and the Lessee&#8217;s
lease of the Facility from the Lessor for an initial term of five years. In March&#160;2017, the right to take title to the Facility under
the Purchase Agreement was assigned to the Lessor, and the Lessor and a syndicate of lenders advanced $720.0 million, which was used by
the Lessor in March&#160;2017 to finance the purchase price for the Facility.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As described in greater detail below, the Original
Participation Agreement and certain related agreements that were originally entered into in March&#160;2017 were amended and restated
in order to, among other things, (i)&#160;effect a five-year extension of the original March&#160;2022 maturity date of the $720.0 million
lease financing and the end of the term of the Lessee&#8217;s lease of the Facility from the Lessor, and (ii)&#160;modify the rate of
the interest or yield that is payable to the Participants (as defined below) on their outstanding advances thereunder.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restated Participation Agreement</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March&#160;2, 2022, the Lessee entered into
a Second Amended and Restated Participation Agreement, dated as of March&#160;2, 2022, and effective as of March&#160;3, 2022 (the &#8220;Restated
Participation Agreement&#8221;) with the Administrative Agent, the Lessor, and a syndicate of financial institutions as rent assignees
(collectively with the Lessor, the &#8220;Participants&#8221;), which amends and restates the Original Participation Agreement. The Restated
Participation Agreement and certain related documents govern the $720.0 million lease financing that was previously advanced in March&#160;2017
to finance the purchase price for the Facility and to reimburse the Company for certain payments previously made by it in connection with
such acquisition.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restated Lease</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Restated Participation Agreement,
the Lessee also entered into a Second Amended and Restated Lease and Remedies Agreement, dated as of March&#160;2, 2022, and effective
as of March&#160;3, 2022 (the &#8220;Restated Lease&#8221;), with the Lessor, which amends, restates, and extends the Lessee&#8217;s lease
of the Facility and certain related assets that was originally entered into in March&#160;2017 by the Lessee and the Lessor. Pursuant
to the Restated Lease, the term of the lease was extended for a five-year period ending in March&#160;2027, and the Lessee has granted
a security interest in certain of its assets and rights to secure certain obligations under the Restated Participation Agreement, the
Restated Lease, and certain related documents. The Restated Lease continues to be a triple-net lease requiring the Lessee, among other
things, to pay during the term of the Restated Lease all maintenance, insurance, taxes, and other costs arising out of the use of the
Facility (which are offset in part by payments received by the Lessee from third-party tenants to whom certain parts of the Facility are
subleased from the Lessee). The Restated Lease also requires that the Lessee make monthly payments of basic rent during the remaining
term of the Restated Lease in an amount equal to the yield payable to the Participants on their outstanding advances under the Restated
Participation Agreement. Such advances accrue yield at a variable rate per annum based on the one-month forward-looking Secured Overnight
Financing (SOFR) term rate, plus a spread adjustment, plus an applicable margin that varies with the Company&#8217;s debt rating and total
leverage ratio.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restated Guaranty</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and its wholly owned subsidiaries Regeneron
Healthcare Solutions,&#160;Inc. and Regeneron Genetics Center LLC, on a joint and several basis, continue to guarantee all of the Lessee&#8217;s
obligations under the Restated Participation Agreement, the Restated Lease, and certain related documents pursuant to a Second Amended
and Restated Guaranty, dated as of March&#160;2, 2022, and effective as of March&#160;3, 2022 (the &#8220;Restated Guaranty,&#8221; and
together with the Restated Participation Agreement and the Restated Lease, the &#8220;Restated Agreements&#8221;), made by the Company
and such subsidiaries, as guarantors.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial and Operating Covenants; Other Terms</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Restated Agreements contain financial and operating
covenants, which are substantially similar to the covenants set forth in that certain Credit Agreement, dated as of December&#160;14,
2018, as previously amended (the &#8220;Credit Agreement&#8221;), by and among the Company, the subsidiary borrowers party thereto from
time to time, the lenders party thereto from time to time, and JPMorgan Chase Bank, N.A., as administrative agent, governing Regeneron&#8217;s
existing revolving credit facility, except for such matters specifically relating to the Facility or the lease financing nature of the
transactions contemplated by the Restated Agreements. Financial covenants include a maximum total leverage ratio and a minimum interest
expense coverage ratio. Operating covenants include, among other things, limitations on (i)&#160;the incurrence of indebtedness by the
Company&#8217;s subsidiaries, (ii)&#160;liens on assets of the Company and its subsidiaries and liens on the Facility, (iii)&#160;certain
fundamental changes and the disposition of assets by the Company and its subsidiaries, (iv)&#160;entering into affiliate transactions,
and (v)&#160;the payment of dividends, distributions, and certain other restricted payments in respect of the capital stock of the Company
and its subsidiaries (the &#8220;Restricted Payments Covenant&#8221;). Similar to the Credit Agreement, the Restricted Payments Covenant
allows the Company, so long as no event of default exists, to make payments that would otherwise be restricted if at the time of the making
of any such payment and immediately thereafter it meets a specified total leverage ratio requirement. The Restated Agreements contain
other customary covenants, representations and warranties, and events of default. The Restated Lease also continues to include certain
early termination events relating to the occurrence of certain material events of loss or material environmental events relating to the
Facility.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Maturity Date; Additional Extension Option;
Termination</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Restated Agreements,
the maturity date for the $720.0 million of advances and the end of the term of the Lessee&#8217;s lease of the Facility from the Lessor
were extended by a five-year period to March&#160;3, 2027, at which time all amounts outstanding thereunder will become due and payable
in full. The Restated Participation Agreement and the Restated Lease include an option for the Lessee to elect to extend the maturity
date of the Restated Participation Agreement and the term of the Restated Lease for an additional five-year period, subject to the consent
of all the Participants and certain other conditions. The Lessee also has the option prior to the end of the term of the Restated Lease
to (a)&#160;purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants&#8217; advances under
the Restated Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Restated Agreements
and certain related documents or (b)&#160;sell the Facility to a third party on behalf of the Lessor, in each case, subject to certain
terms and conditions set forth in the Restated Participation Agreement and the Restated Lease. Outstanding advances under the Restated
Participation Agreement and outstanding obligations under the Restated Lease may be prepaid at any time without premium or penalty, subject
to customary breakage costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description
of the Restated Participation Agreement, the Restated Lease, and the Restated Guaranty is qualified in its entirety by reference to the
full and complete text of such agreements, copies of which are attached hereto as Exhibits 10.1, 10.2, and 10.3, respectively, and are
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2.03. Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth
in Item 1.01 above with respect to the Restated Agreements is hereby incorporated by reference into this Item 2.03 insofar as it relates
to the creation of a direct financial obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 23pt">(d)</td><td>Exhibits.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-left: 225pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 10%"><a href="tm222431d2_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></a></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 88%"><a href="tm222431d2_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Participation Agreement, dated as of March&#160;2, 2022, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm222431d2_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm222431d2_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Lease and Remedies Agreement, dated as of March&#160;2, 2022, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm222431d2_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm222431d2_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Guaranty, dated as of March&#160;2, 2022, made by Regeneron Pharmaceuticals,&#160;Inc., Regeneron Healthcare Solutions,&#160;Inc., and Regeneron Genetics Center LLC, as guarantors.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File - the cover page&#160;XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Certain of the exhibits and/or schedules to this Exhibit&#160;have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGENERON PHARMACEUTICALS,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March&#160;8, 2022</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph J. LaRosa</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph J. LaRosa</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, General Counsel and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
